Literature DB >> 18673131

Inhibitors of c-jun-N-terminal kinase (JNK).

Philip LoGrasso1, Theodore Kamenecka.   

Abstract

Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18673131     DOI： 10.2174/138955708784912120

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  18 in total

1.  Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.

Authors:  Romain Noël; Youseung Shin; Xinyi Song; Yuanjun He; Marcel Koenig; Weimin Chen; Yuan Yuan Ling; Li Lin; Claudia H Ruiz; Phil LoGrasso; Michael D Cameron; Derek R Duckett; Theodore M Kamenecka
Journal:  Bioorg Med Chem Lett       Date:  2010-12-01       Impact factor: 2.823

Review 2.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

3.  Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.

Authors:  Yuanjun He; Derek Duckett; Weimin Chen; Yuan Yuan Ling; Michael D Cameron; Li Lin; Claudia H Ruiz; Philip V Lograsso; Theodore M Kamenecka; Marcel Koenig
Journal:  Bioorg Med Chem Lett       Date:  2013-12-04       Impact factor: 2.823

4.  Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.

Authors:  Ke Zheng; Chul Min Park; Sarah Iqbal; Pamela Hernandez; HaJeung Park; Philip V LoGrasso; Yangbo Feng
Journal:  ACS Med Chem Lett       Date:  2015-03-02       Impact factor: 4.345

5.  Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor.

Authors:  Nancy-Ellen Haynes; Nathan R Scott; Li C Chen; Cheryl A Janson; Jia Kui Li; Christine M Lukacs; Aruna Railkar; Effie Tozzo; Toni Whittard; Nicholas F Brown; Adrian Wai-Hing Cheung
Journal:  ACS Med Chem Lett       Date:  2012-08-08       Impact factor: 4.345

6.  Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors.

Authors:  Yuanjun He; Theodore M Kamenecka; Youseung Shin; Xinyi Song; Rong Jiang; Romain Noel; Derek Duckett; Weimin Chen; Yuan Yuan Ling; Michael D Cameron; Li Lin; Susan Khan; Marcel Koenig; Philip V LoGrasso
Journal:  Bioorg Med Chem Lett       Date:  2011-01-22       Impact factor: 2.823

7.  Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.

Authors:  Ted Kamenecka; Rong Jiang; Xinyi Song; Derek Duckett; Weimin Chen; Yuan Yuan Ling; Jeff Habel; John D Laughlin; Jeremy Chambers; Mariana Figuera-Losada; Michael D Cameron; Li Lin; Claudia H Ruiz; Philip V LoGrasso
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

8.  Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors.

Authors:  Youseung Shin; Weiming Chen; Jeff Habel; Derek Duckett; Yuan Yuan Ling; Marcel Koenig; Yuanjun He; Tomas Vojkovsky; Philip LoGrasso; Theodore M Kamenecka
Journal:  Bioorg Med Chem Lett       Date:  2009-03-26       Impact factor: 2.823

9.  Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Andrei S Potapov; Anastasia R Kovrizhina; Vladislava V Matveevskaya; Maxim L Belyanin; Dmitriy N Atochin; Svitlana O Zanoza; Nadiya M Gaidarzhy; Sergiy A Lyakhov; Liliya N Kirpotina; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2018-10-12       Impact factor: 6.514

Review 10.  Mitogen activated protein kinases: a role in inflammatory bowel disease?

Authors:  O J Broom; B Widjaya; J Troelsen; J Olsen; O H Nielsen
Journal:  Clin Exp Immunol       Date:  2009-09-30       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.